~~<i id='135D6EC093'><strike id='135D6EC093'><tt id='135D6EC093'><pre id='135D6EC093'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：leisure time 2025-10-04 07:08:27 Page View：11645

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Experts study whether long Covid risk adds up with each reinfection
Next article： Novavax promises a turnaround & Lilly roils the obesity market

explore

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

CDC picks Alphabet's Verily for wasterwater surveillance contract

AdobeAlphabet’slifesciencescompanyVerilyhasscoreditsfirstCentersforDiseaseControlandPreventioncontra

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

Moderna says combo Covid

AlexHogan/STATModernaannouncedMondaythat,inaPhase3clinicaltrial,itscombinationCovid-19andinfluenzava